Capital Asset Advisory Services LLC Has $2.79 Million Stock Holdings in Pfizer Inc. $PFE

Capital Asset Advisory Services LLC grew its holdings in Pfizer Inc. (NYSE:PFE) by 51.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 109,430 shares of the biopharmaceutical company’s stock after acquiring an additional 37,402 shares during the quarter. Capital Asset Advisory Services LLC’s holdings in Pfizer were worth $2,788,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the business. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer in the first quarter valued at approximately $27,000. Curio Wealth LLC raised its holdings in shares of Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new stake in Pfizer in the 1st quarter valued at $28,000. Harbor Asset Planning Inc. acquired a new position in Pfizer in the 2nd quarter worth $29,000. Finally, Howard Hughes Medical Institute bought a new position in Pfizer during the 2nd quarter worth about $30,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on PFE shares. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Bank of America cut their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 price target on shares of Pfizer in a research note on Wednesday, November 5th. Morgan Stanley lowered their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday. Finally, Citigroup initiated coverage on shares of Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $28.22.

Pfizer Trading Up 2.3%

NYSE PFE opened at $26.45 on Tuesday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The stock has a 50 day moving average of $25.12 and a 200-day moving average of $24.80. The company has a market cap of $150.37 billion, a PE ratio of 15.38 and a beta of 0.46.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.5%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.